Skip to main content

Table 3 Treatment difficulty and non-adherence among CML patients, according to current CML treatment

From: Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

  Imatinib Dasatinib Nilotinib Imatinib vs. Dasatinib Imatinib vs. Nilotinib Dasatinib vs. Nilotinib
  (N=208) (N=38) (N=49)    
  Mean, N SD, % Mean, N SD, % Mean, N SD, % p-value p-value p-value
Treatment Difficulty          
 Yes 40 19.23% 1 2.63% 31 63.27% 0.01 <.01 <.01
 No 168 80.77% 37 97.37% 18 36.73% 0.01 <.01 <.01
Non-Adherence          
 No. Missed Doses 0.45 1.08 0.63 1.73 1.02 1.60 0.54 0.02 0.29
 No. Skipped Doses 0.41 1.53 0.53 1.83 0.73 1.62 0.72 0.21 0.58
 No. Doses Less than Prescribed 0.10 0.52 1.05 4.78 0.47 1.46 0.23 0.08 0.47
  1. Note: CML=Chronic Myeloid Leukemia, No.=Number of, SD=Standard Deviation.